Key Points
- Samarth Kulkarni, CRISPR's CEO, sold 30,000 shares on Jan 20 at $51.75 for $1,552,500 and a further 60,000 shares on Jan 22 at $60.23 for $3,613,800, reducing his ownership by 13.38% to 194,201 shares (worth about $10.05M).
- Shares jumped about 10.8%, opening at $60.66, with a market cap of $5.78 billion and a 12‑month trading range of $30.04 to $78.48 (50‑/200‑day moving averages $54.88 / $58.35).
- Recent results showed negative EPS (‑$1.17 last quarter) and revenue below estimates, and analysts carry a consensus "Hold" rating with a $68.35 target (12 Buys, 8 Holds, 2 Sells).
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $51.75, for a total value of $1,552,500.00. Following the transaction, the chief executive officer directly owned 194,201 shares of the company's stock, valued at $10,049,901.75. This trade represents a 13.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Samarth Kulkarni also recently made the following trade(s):
- On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00.
CRISPR Therapeutics Stock Up 10.8%
Shares of CRISPR Therapeutics stock opened at $60.66 on Friday. The stock has a market cap of $5.78 billion, a P/E ratio of -10.85 and a beta of 1.70. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $78.48. The business's 50 day moving average is $54.88 and its 200-day moving average is $58.35.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The business had revenue of $0.89 million for the quarter, compared to the consensus estimate of $8.74 million. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in CRSP. Orbis Allan Gray Ltd boosted its position in shares of CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company's stock valued at $134,467,000 after acquiring an additional 1,201,600 shares during the period. Geode Capital Management LLC boosted its holdings in CRISPR Therapeutics by 98.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company's stock valued at $100,789,000 after purchasing an additional 1,025,979 shares during the period. SR One Capital Management LP boosted its holdings in CRISPR Therapeutics by 94.4% in the 3rd quarter. SR One Capital Management LP now owns 2,038,763 shares of the company's stock valued at $132,132,000 after purchasing an additional 989,812 shares during the period. State Street Corp grew its position in shares of CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company's stock worth $159,082,000 after purchasing an additional 859,334 shares in the last quarter. Finally, Norges Bank bought a new position in shares of CRISPR Therapeutics during the second quarter worth approximately $19,772,000. Institutional investors own 69.20% of the company's stock.
Analyst Ratings Changes
CRSP has been the subject of a number of research analyst reports. Bank of America lifted their price target on CRISPR Therapeutics from $78.00 to $93.00 and gave the stock a "buy" rating in a report on Friday, October 17th. Wedbush reduced their target price on CRISPR Therapeutics from $13.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday, November 5th. Royal Bank Of Canada boosted their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a "sector perform" rating in a report on Tuesday, November 11th. Citigroup reaffirmed a "buy" rating and set a $77.00 price target (down previously from $87.00) on shares of CRISPR Therapeutics in a report on Tuesday, November 11th. Finally, Wells Fargo & Company set a $75.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, October 13th. Twelve equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $68.35.
Get Our Latest Report on CRISPR Therapeutics
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.
Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
